ADDIS ABABA, ETHIOPIA — The Ethiopian Food and Drug Authority (EFDA) has issued an urgent medical product alert concerning an unauthorized medicine known as Duphaston 10 mg, which has illegally entered the country’s commercial supply chain.
According to the authority, the medicine is used to treat conditions associated with disorders of the female reproductive system and hormonal imbalances and is available only with a doctor’s prescription.
Duphaston 10 mg is primarily used in various infertility treatments, pregnancy support, endometriosis treatment, and hormone replacement therapy.
According to information submitted to the authority by the manufacturer, Abbott Laboratories, the product entered the market illegally without the knowledge or authorization of the Ethiopian Food and Drug Authority.
The authority has identified several differences between the legally authorized product and the unauthorized medicine.
The legally authorized product contains only 20 tablets in a single package, while the unauthorized product contains three individual packages, totaling 60 tablets.
The authorized product is packaged by Abbott Laboratories itself, whereas the unauthorized product appears to have been manufactured for the Egyptian market.
Another distinguishing feature is the language used on the product packaging. The legally authorized medicine includes information in English, Spanish and Portuguese, while the unauthorized product contains information only in English and Arabic.
The authorized product also carries domestic regulatory information on the back of the package, including its Ethiopian registration details. However, this regulatory information is entirely absent or inconsistent on the unauthorized product.
The authority warned that because the medicine entered Ethiopia illegally, its quality, safety and effectiveness have not been verified by the regulator, potentially posing a risk to public health.
Consequently, health institutions, pharmacies and healthcare professionals have been urged to remove the unauthorized product from the supply chain.
Patients have also been advised to refrain from using the medicine, according to information published on the Ethiopian Food and Drug Authority’s social media page.